25 Sep Coronavirus vaccine: Who will be first to get jab? Draft list revealed | UK News
A draft list has been published showing who is likely to be at the front of the queue for a jab when a coronavirus vaccine is approved in the UK.
The government’s Joint Committee On Vaccination And Immunisation say they recommend a “simple age-based programme” to make the decisions around who gets priority.
This approach “will likely result in faster delivery and better uptake in those at the highest risk”, they said.
Here’s their provisional priority list:
- Older adults’ resident in a care home and care home workers
- All those 80 years of age and over and health and social care workers
- All those 75 years of age and over
- All those 70 years of age and over
- All those 65 years of age and over
- High-risk adults under 65 years of age
- Moderate-risk adults under 65 years of age
- All those 60 years of age and over
- All those 55 years of age and over
- All those 50 years of age and over
- Rest of the population (priority to be determined)
The committee added: “Whether health and social care workers should be prioritised above, alongside, or below, persons at highest risk from COVID-19 would depend on the characteristics of the vaccines when they become available and the epidemiology of disease at the time of delivery.”
There are almost 40 potential vaccines being tested globally and more than 140 others in the early stages of testing, according to the World Health Organisation.
However, experts told Sky News that just one in 10 of the world’s population is likely to be protected against COVID-19 in the first year of a vaccine being made available.
Analysis of global manufacturing capacity shows just two billion doses could be made in 2021 even if they are given the green light.
Russia claims to be the frontrunner, having already developed what the nation says is an effective vaccine – despite skipping the usual rounds of testing.
Eight others are in phase three trials – the last step to becoming licensed.
One of the frontrunners in this category is the jab being developed by Oxford University and AstraZeneca who were the first to reach this critical stage.
Pharmaceutical giants Pfizer and Moderna are also making good progress and could soon have a vaccine ready.
And on Friday, US biotechnology firm Novavax announced it was starting its phase three trials in the UK.
The US biotechnology firm is to enrol 10,000 people out of 250,000 volunteers aged between 18 and 84 over the next four to six weeks.
Meanwhile, countries in the northern hemisphere are having difficulties sourcing flu vaccines, according to the World Health Organisation (WHO).
There is increased demand for the influenza jab this year amid the global coronavirus pandemic, as people scramble to protect themselves ahead of winter.
However, the WHO did not reveal which specific countries were struggling to acquire the vaccines.